ANVISA Medical Device and IVD Registration in Brazil

Regulatory Governance and Strategic Overview

The commercialization of medical devices and In Vitro Diagnostic (IVD) products in Brazil is strictly overseen by the National Health Surveillance Agency (ANVISA). As the Brazilian regulatory landscape achieves deeper harmonization with International Medical Device Regulators Forum (IMDRF) standards, global manufacturers must navigate a sophisticated hierarchy of Resolutions (RDCs) to secure and maintain market access.

The Brazilian healthcare market operates under a robust legal framework that emphasizes pre-market scrutiny and post-market vigilance. For international manufacturers, understanding the intersection of federal laws and specific ANVISA technical resolutions is essential. These regulations ensure that healthcare technologies meet established safety and performance benchmarks before distribution. The complexity of this environment requires a strategic approach to documentation and quality management alignment to ensure sustained compliance within the national healthcare system.

Principal Regulatory Foundations (2026 Updated)

• RDC 751/2022 – The primary framework for medical device risk classification and market authorization, aligning Brazil's requirements with the EU MDR.
• RDC 830/2023 – The definitive mandate for IVD products, implementing modernized classification rules and technical documentation requirements.
• RDC 687/2022 & RDC 850/2024 – Regulations governing Brazil Good Manufacturing Practices (B-GMP), including the latest streamlined pathways for MDSAP-audited facilities.
• RDC 546/2021 – Establishes essential safety and performance requirements that must be demonstrated in the technical dossier for all medical devices.

Risk-Based Classification Pathways

Under the mandates of RDC 751/2022 and RDC 830/2023, the regulatory pathway is determined by the inherent risk profile of the technology. Precision in initial classification is critical to optimizing time-to-market and determining the necessary level of clinical evidence.

For Class III and IV devices, the "Registro" pathway involves a comprehensive technical review. Manufacturers must submit a detailed dossier including clinical data, stability studies, and risk management files. ANVISA evaluates these submissions to ensure that clinical benefits outweigh any potential risks under normal conditions of use.

Core Compliance Pillars for Global Manufacturers

Brazil Registration Holder (BRH) Requirement

Foreign manufacturers without a direct legal presence in Brazil are mandated to appoint a Brazil Registration Holder (BRH). The BRH serves as the legal titleholder of the registration and the primary liaison with ANVISA. This entity is responsible for submitting all regulatory documents and managing post-market surveillance activities. Appointing an independent, third-party BRH ensures maximum control over intellectual property and preserves the flexibility to manage multiple distributors without regulatory lock-in.

Brazil Good Manufacturing Practices (B-GMP)

For high-risk devices (Class III and IV), proof of B-GMP compliance is non-negotiable. This certification confirms that the manufacturing site adheres to quality management standards equivalent to ISO 13485 with specific Brazilian deviations. Since 2024, ANVISA has increasingly streamlined the B-GMP process for manufacturers participating in the Medical Device Single Audit Program (MDSAP). This allows for faster certification through audit report recognition, potentially bypassing the need for a physical on-site inspection.

Technical Documentation and Language Protocols

The preparation of technical documentation requires careful attention to language and formatting standards. While ANVISA may accept certain technical reports and supporting data in English or Spanish, the instructions for use (IFU) and product labeling must be provided in Brazilian Portuguese. These documents must be localized to ensure that technical nomenclature and safety warnings are clearly understood by Brazilian healthcare professionals and patients. Accuracy in these translations is a fundamental requirement for successful dossier approval.

Proregulations' Brazil Medical Device and IVD Registration Services

Our standardized service process facilitates the efficient navigation of the ANVISA registration pathway for medical device and IVD portfolios during regulatory transition periods. We offer a comprehensive suite of solutions to manage every stage of the market access lifecycle:

• Regulatory strategy and classification
  We conduct in-depth assessments under RDC 751/2022 and RDC 830/2023 to determine the most efficient pathway for your technology.
• Technical dossier compilation
  Our experts manage the preparation, translation, and submission of the technical dossier, ensuring alignment with ANVISA's rigorous review standards.
• B-GMP and MDSAP support
  We provide strategic guidance on quality management system alignment and facilitate B-GMP certification through the MDSAP pathway.
• INMETRO and ANATEL coordination
  We manage the interface with testing laboratories and certification bodies to secure necessary electrical safety and telecommunications approvals.
• BRH representation
  We provide independent Brazil Registration Holder services, allowing you to maintain full control over your market authorizations and distribution strategy.
• Post-market surveillance
  We assist with vigilance reporting, registration renewals, and compliance management for post-market changes.

If you are interested in our Brazil compliance services and wish to accelerate your market entry through robust regulatory strategies, please feel free to contact us.